{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:54:49Z","timestamp":1791320089615,"version":"4.3.1"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":350,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jcph.393","type":"journal-article","created":{"date-parts":[[2014,9,4]],"date-time":"2014-09-04T23:32:02Z","timestamp":1409873522000},"page":"221-229","source":"Crossref","is-referenced-by-count":25,"title":["Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease"],"prefix":"10.1002","volume":"55","author":[{"given":"Chuanpu","family":"Hu","sequence":"first","affiliation":[{"name":"Model Based Drug Development, Janssen Research and Development; LLC; Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omoniyi","family":"Adedokun","sequence":"additional","affiliation":[{"name":"Model Based Drug Development, Janssen Research and Development; LLC; Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ito","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.; Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Raje","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.; Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Model Based Drug Development, Janssen Research and Development; LLC; Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,16]]},"reference":[{"key":"10.1002\/jcph.393-BIB0001|jcph393-cit-0001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1002\/jcph.393-BIB0002|jcph393-cit-0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/B:JOPA.0000034404.86036.72","article-title":"Power, selection bias and predictive performance of the population pharmacokinetic covariate model","volume":"31","author":"Ribbing","year":"2004","journal-title":"J Pharm Pharmacodyn"},{"key":"10.1002\/jcph.393-BIB0003|jcph393-cit-0003","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"key":"10.1002\/jcph.393-BIB0004|jcph393-cit-0004","first-page":"S1","article-title":"A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision","volume":"6","author":"Gastonguay","year":"2004","journal-title":"AAPS J"},{"key":"10.1002\/jcph.393-BIB0005|jcph393-cit-0005","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1002\/sim.2786","article-title":"Estimating the predictive quality of dose-response after model selection","volume":"26","author":"Hu","year":"2007","journal-title":"Stat Med"},{"key":"10.1002\/jcph.393-BIB0006|jcph393-cit-0006","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1198\/016214504000001097","article-title":"Inference after model selection","volume":"99","author":"Shen","year":"2004","journal-title":"J Am Stat Assoc"},{"key":"10.1002\/jcph.393-BIB0007|jcph393-cit-0007","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/0091270008318670","article-title":"An improved approach for confirmatory phase III population pharmacokinetic analysis","volume":"48","author":"Hu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jcph.393-BIB0008|jcph393-cit-0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pst.403","article-title":"Confirmatory analysis for phase III population pharmacokinetics","volume":"10","author":"Hu","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1002\/jcph.393-BIB0009|jcph393-cit-0009","volume-title":"Drug-Drug Interaction for Therapeutic Biologics","author":"Hu","year":"2013"},{"key":"10.1002\/jcph.393-BIB0010|jcph393-cit-0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jcph.240","article-title":"Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions","volume":"54","author":"Chow","year":"2014","journal-title":"J Clin Pharmcol"},{"key":"10.1002\/jcph.393-BIB0011|jcph393-cit-0011","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","article-title":"Learning versus confirming in clinical drug development","volume":"61","author":"Sheiner","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jcph.393-BIB0012|jcph393-cit-0012","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1002\/jcph.393-BIB0013|jcph393-cit-0013","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-014-9366-0","article-title":"Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint","author":"Hu","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1002\/jcph.393-BIB0014|jcph393-cit-0014","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2"},{"key":"10.1002\/jcph.393-BIB0015|jcph393-cit-0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0091270009339192","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis","volume":"49","author":"Xu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jcph.393-BIB0016|jcph393-cit-0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jcph.393-BIB0017|jcph393-cit-0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"10.1002\/jcph.393-BIB0018|jcph393-cit-0018","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"10.1002\/jcph.393-BIB0019|jcph393-cit-0019","unstructured":"Holford NHG http:\/\/www.page-meeting.org\/default.asp?abstract=738 2005"},{"key":"10.1002\/jcph.393-BIB0020|jcph393-cit-0020","doi-asserted-by":"crossref","DOI":"10.1201\/9780429246593","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"key":"10.1002\/jcph.393-BIB0021|jcph393-cit-0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1002\/jcph.393-BIB0022|jcph393-cit-0022","volume-title":"NONMEM User's Guides (1989-2009)","author":"Beal","year":"2009"},{"key":"10.1002\/jcph.393-BIB0023|jcph393-cit-0023","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425250902992901","article-title":"Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics","volume":"5","author":"Gibiansky","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1002\/jcph.393-BIB0024|jcph393-cit-0024","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0091270009339192","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-a human monoclonal antibody, in patients with psoriatic arthritis","volume":"49","author":"Xu","year":"2010","journal-title":"J Clin Pharm"},{"issue":"3","key":"10.1002\/jcph.393-BIB0025|jcph393-cit-0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10928-014-9360-6","article-title":"Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of a related therapeutic proteinguselkumab in patients with moderate-to-severe psoriasis","volume":"41","author":"Hu","year":"2014","journal-title":"J Pharm Pharmacodyn"},{"key":"10.1002\/jcph.393-BIB0026|jcph393-cit-0026","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4161\/mabs.2.5.12833","article-title":"Properties of a general PK\/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets","volume":"2","author":"Davda","year":"2010","journal-title":"MAbs"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.393","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:54Z","timestamp":1657803834000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,16]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.393","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9,16]]}}}